You are here: Home » PTI Stories » National » News
Business Standard

Lupin gets USFDA nod for generic Armodafinil tablets

Press Trust of India  |  New Delhi 

Drug major today said it has received approval from the US health regulator to market its Armodafinil tablets, indicated to improve wakefulness, in the American market.

The company's US-based subsidiary Pharmaceuticals, Inc (LPI) has received final approval for Armodafinil tablets in strengths of 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration (FDA), Ltd said in a statement.



The company's product is a generic version of Cephalon, Inc's Nuvigil tablets which is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD).

"LPI shall commence promoting the product in the US shortly," the Mumbai-based company said.

This is the second approval that has received in the last six days from its manufacturing facility. The company had earlier received a tentative approval for Generic Epzicom tablets.

Last month the USFDA had cleared Lupin's plant of violations of good manufacturing practices (cGMP) observed during an inspection in March 2016.

As per IMS sales data, Nuvigil tablets had US sales of USD 515.6 million.

shares today ended 0.82 per cent up at Rs 1,517.05 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Lupin gets USFDA nod for generic Armodafinil tablets

Drug major Lupin today said it has received approval from the US health regulator to market its Armodafinil tablets, indicated to improve wakefulness, in the American market. The company's US-based subsidiary Lupin Pharmaceuticals, Inc (LPI) has received final approval for Armodafinil tablets in strengths of 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration (FDA), Lupin Ltd said in a statement. The company's product is a generic version of Cephalon, Inc's Nuvigil tablets which is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD). "LPI shall commence promoting the product in the US shortly," the Mumbai-based company said. This is the second approval that Lupin has received in the last six days from its Goa manufacturing facility. The company had earlier received a tentative approval for Generic Epzicom tablets. Last month ... Drug major today said it has received approval from the US health regulator to market its Armodafinil tablets, indicated to improve wakefulness, in the American market.

The company's US-based subsidiary Pharmaceuticals, Inc (LPI) has received final approval for Armodafinil tablets in strengths of 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration (FDA), Ltd said in a statement.

The company's product is a generic version of Cephalon, Inc's Nuvigil tablets which is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD).

"LPI shall commence promoting the product in the US shortly," the Mumbai-based company said.

This is the second approval that has received in the last six days from its manufacturing facility. The company had earlier received a tentative approval for Generic Epzicom tablets.

Last month the USFDA had cleared Lupin's plant of violations of good manufacturing practices (cGMP) observed during an inspection in March 2016.

As per IMS sales data, Nuvigil tablets had US sales of USD 515.6 million.

shares today ended 0.82 per cent up at Rs 1,517.05 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Lupin gets USFDA nod for generic Armodafinil tablets

Drug major today said it has received approval from the US health regulator to market its Armodafinil tablets, indicated to improve wakefulness, in the American market.

The company's US-based subsidiary Pharmaceuticals, Inc (LPI) has received final approval for Armodafinil tablets in strengths of 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration (FDA), Ltd said in a statement.

The company's product is a generic version of Cephalon, Inc's Nuvigil tablets which is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD).

"LPI shall commence promoting the product in the US shortly," the Mumbai-based company said.

This is the second approval that has received in the last six days from its manufacturing facility. The company had earlier received a tentative approval for Generic Epzicom tablets.

Last month the USFDA had cleared Lupin's plant of violations of good manufacturing practices (cGMP) observed during an inspection in March 2016.

As per IMS sales data, Nuvigil tablets had US sales of USD 515.6 million.

shares today ended 0.82 per cent up at Rs 1,517.05 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard